Skip to main content
TipRanks
Go Ultimate75% OFF

Hikma Pharmaceuticals (H5P) Q2 2026 Earnings Report

4 Followers

DE:H5P Q2 2026 EPS Results

Actual EPS
EUR 1.12
Consensus EPS
EUR 0.98
Beat/Miss
Beat by +EUR 0.14
One Year Ago EPS
EUR 1.08

DE:H5P Q2 2026 Revenue Results

Actual Revenue
EUR 1.54B
Expected Revenue
EUR 1.51B
Beat/Miss
Beat by +EUR 26.46M
YoY Revenue Growth
+0.47%

Earnings Announcement Details

Quarter
Q2 2026
Date
08/06/2026
Time
Before Open
Conference Call
Thursday, August 6, 2026
DE:H5P Upcoming Earnings

Hikma Pharmaceuticals's next earnings date is estimated for February 25, 2027, based on past reporting schedules.

Q2 2026 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q2 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Aug 06, 2026|% Change Since:11.07%|
Earnings Call Sentiment|Neutral

The call conveyed balanced progress: strong H1 operational and financial performance (EBIT/EBITDA up ~8%, EPS up ~5%), clear operational fixes in injectables, solid MENA momentum, advancing product launches (TYZAVAN, tapentadol) and CMO pipeline, and near‑term proof of capital return via buybacks. Offsetting this are meaningful H2 risks (historical H1 tender weighting and stockpiling normalisation), ongoing price erosion in parts of Rx, divestment of a loss‑making 503B unit, and elevated H2 investment that will temper near‑term margins. Management reiterated full‑year guidance and emphasised continued investment for medium‑term growth (CMO, R&D, US capacity). Overall the positives are meaningful but matched by tangible short‑term headwinds and execution/market risks.

Company Guidance

Hikma reiterated its FY2026 guidance of group revenue growth of 2–4% and operating profit of $720–$770m (H1 operating profit was $405m), after H1 delivered EBIT and EBITDA up almost 8% and EPS up ~5%; management said branded/tender sales are H1‑weighted (around 55% of sales in H1), R&D and promotion spend will increase in H2, and inflation has been absorbed so far. Other metrics called out: buyback ~complete (~$230m spent to buy ~11–12m shares, ~$20m remaining), ~80% of Vanco Ready customers have switched to TYZAVAN, injectable and CMO revenues are expected to pick up in H2 (Rx CMO still tracking to a 20% of Rx‑revenue target by 2030), the 503B compounding unit is classified as held for sale (expected within 12 months), and major capacity additions (Bedford plant due in 2028) underpin the outlook.

  • Profitability Improvement (EBIT / EBITDA)EBIT and EBITDA increased by almost 8% in H1 2026, reflecting stronger operating performance and margin management.
  • EPS GrowthEPS rose by c.5% year-on-year, demonstrating earnings per share growth alongside higher operating profits.
  • Revenue Growth and Guidance ReiterationSales were reported as up in H1 2026 and management reiterated full‑year guidance (group revenue growth guidance of 2%–4% and operating profit guidance of $720m–$770m). H1 operating profit reported was $405m.
  • MENA OutperformanceMENA region delivered 'extremely well' and is cited as a primary growth engine; Hikma is now #1 in oncology in MENA and management highlighted strong product launches and market share gains across Saudi Arabia, Algeria and Egypt.
  • Injectables Business StabilizedManagement reports the injectables business is stabilised after operational fixes (hiring, equipment and supply chain improvements), with safety stocks built and higher production run‑rates; R&D investment for injectables has increased significantly and submission cadence is accelerating for 2028+ growth.
  • TYZAVAN AdoptionTYZAVAN adoption progressing: ~80% of Vanco Ready customers have switched or partially switched to TYZAVAN; month‑by‑month uptake expected to accelerate into H2 2026 and 2027 with further hospital group conversions.
  • Strong Rx LaunchesTapentadol (authorized generic) launched strongly; broader Rx launch pipeline includes epinephrine nasal spray (submission made; awaiting FDA acceptance) and ongoing product approvals/launches expected to support future growth.
  • CMO Momentum and Medium‑term TargetManagement expects CMO revenues (injectables and Rx) to pick up in H2 2026 and is tracking to a target of c.20% of Rx revenue from CMO by 2030; a major Rx CMO contract is ramping with expectations of full commercial production in 2027.
  • Investment in R&D, People and U.S. ManufacturingR&D spend is higher, significant hiring across functions, and continued investment in U.S. capacity (notably Cherry Hill and Bedford plants) with ~$50m in incentives from the state of Ohio (c.$5m per year up to $50m) supporting expansion.
  • Share Buyback Near CompletionBuyback program largely completed with c.$230m deployed and approximately 11–12m shares repurchased; only a small residual amount remains.
  • Legal / Reputation WinFavorable Supreme Court outcome in the Amarin case noted as a notable industry and reputational win for Hikma and the generic industry.

DE:H5P Earnings History

DE:H5P earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 25, 20272026 (Q4)1.00-0.67――
Aug 06, 20262026 (Q2)0.981.121.083.28% (+0.04)
Feb 26, 20262025 (Q4)0.960.670.5619.06% (+0.11)
Aug 07, 20252025 (Q2)1.001.081.13-3.94% (-0.04)
Feb 26, 20252024 (Q4)―0.560.26118.22% (+0.30)
Aug 08, 20242024 (Q2)―1.131.14-0.70% (-0.01)
Feb 22, 20242023 (Q4)―0.261.06-75.87% (-0.81)
Aug 03, 20232023 (Q2)0.841.140.8139.48% (+0.32)
Feb 23, 20232022 (Q4)0.690.790.86-8.56% (-0.07)
Aug 04, 20222022 (Q2)0.860.810.85-4.58% (-0.04)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed